• 出版社/出版日：Mordor Intelligence / 2021年7月26日
|Single User||￥561,000 (USD4,250)||▷ お問い合わせ|
|Team User||￥627,000 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥990,000 (USD7,500)||▷ お問い合わせ|
・競争状況（AbbVie Inc (Allergan Plc)、Anika Therapeutics Inc.、Ipsen SA、Medytox Inc.、Merz Pharma、Galderma Pharma SA、Sanofi SA、Sinclair Pharma Plc、Suneva Medical Inc.、Teoxane Laboratories、Laboratories Vivacy SAS、SciVision Biotech Inc.）
The Facial Injectables market is expected to register a CAGR of nearly 12.2% during the forecast period.
The contagious coronavirus has a potential economic impact and implications on most of the sectors, including the medical device industries. Governments worldwide are now responding to the threat of COVID-19 with all the essential measures, such as social distancing, travel restrictions, and large-scale quarantines that are anticipated to impact the businesses and consumer spending negatively. The outbreak of COVID-19, resulted in decreased public mobility and have also impacted the therapeutic and surgical industry significantly, as the surgical procedures and screening programs, which are non-immediate and are being postponed to decrease the burden on healthcare infrastructure.
According to the research study by Hassan Galadari et al., published in Dermatologic Therapy June 2020, globally, COVID-19 spreads around the globe has become evident that this virus has the ability to significantly derail the world economy. The past 5 years have seen a boom in both minimally invasive and surgical cosmetic procedures but COVID-19 outbreak has shown impact on market growth. As the coronavirus pandemic has grown in magnitude, the safety of these procedures have become questionable.
According to the study published in the British Journal of Surgery, in May 2020, based on a 12-week period of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide will be canceled or postponed in 2020.
In addition, rising cases of COVID–19 in some countries such as India are expected to have a short-term impact on surgical rates of cosmetic procedures. The short-term effects on the surgical segment are less prominent. However, the adverse impacts of COVID-19 on the global economy can have significant indirect effects on the surgical segment of the market.
The propelling factors for the growth of the facial injectables market include the rising aesthetic consciousness and number of cosmetic procedures, the introduction of cost-effective facial injectable, and the aging population.
The cosmetic industry is found to be booming in the current decade and has undergone an estimated three-fold increase in turnover over the last few decades. In particular, there has been an increase in the total number of non-surgical therapies, such as injections of wrinkle relaxers and dermal fillers. This trend is primarily due to the advantages of technologies, such as low recovery time, less risk of infections, no blood loss, and the overall reduction in procedural costs. Thus, the increase in the number of cosmetic procedures has spurred the growth of the overall market.
In addition, there is a consistent rise in the geriatric population that helps to boost the market growth. For instance, according to the World Ageing 2019 report, in 2019, there were around 703 million population aged 65 years or over in the world. The number of older persons is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 6% in 1990 to 9% in 2019. Along with the aging population, the new generation has been attracted to the cosmetic industry to appear more youthful. Furthermore, technological advancements are also helping in the growth of the market.
The market players are adopting various strategies such as product launches, developments, collaborations, partnerships, acquisitions and expansions to increase market share. For instance, in February 2019, the United States Food and Drug Administration (FDA) approved, Jeuveau which is found to be effective in reducing wrinkles. Thus, owing to above mentioned factors it is likely to drive the market growth. However, factors such as side-effects of available products limiting adoption and lack of reimbursement policies supporting cosmetic procedures are likely to impede market growth in near future.
Key Market Trends
Hyaluronic Acid Segment is Expected to Hold Significant Share Over the Forecast Period
Some of the factors that are responsible for Hyaluronic acid segment growth inlcude known for its ability to store moisture in the skin, thus making the skin look healthier, moisture-binding characteristic that helps enhance and maintain the vital moisture responsible for the plumpness of the facial skin. The increasing demand for aesthetic procedures and increasing number of facial procedures is boosting the segment growth.
According to a research article by Matt Spick et al., published in September 2020, found that most of the people infected with SARS-COV-2 coronavirus are likely to develop dyslipidemia and changes in their sebum lipodome that can lead to premature aging of the skin in the long term which is expected to boost market growth in coming years.
Furthermore, according to a survey by Hamilton Fraser Cosmetic Insurance, that was conducted in March 2020, with 1,360 cosmetic practitioners in the United Kingdom to assess the impact of the pandemic, 99.78% of the practitioners said that their practice had been affected by the virus.
Hyaluronic acid has major benefits as it increases hydration, improves elasticity, and reverses free radical damage that protects from UV damage. These factors help in driving the overall market for hyaluronic acid. It is also seen that the demand for hyaluronic acid is increasing significantly, which is expected to provide consistent growth in the coming years in the studied market.
The market players are adopting various strategies such as product launches, developments, collaborations, partnerships, acquisitions and expansions to increase market share. For instance, in June 2020, AbbVie Inc., (Allergan Plc) received approval from United States Food and Drug Administration (FDA) for JUVÉDERM VOLUMA XC for the augmentation of the chin region in adults over the age of 21.
In addition, in September 2018, Croma Pharma GmbH established a joint venture company with China National Biotech Group Company Ltd. to market its premium Hyaluronic Acid Filler Princess VOLUME and various additional aesthetic products of Croma in China and Hong Kong. Thus, owing to above mentioned factors it is likely to drive the segment growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
Some of the factors that are driving the market growth in North America region include higher awareness about aesthetic surgical procedures, technological advancements in cosmetic procedures, presence of key market players and increasing geriatric population and demand for non-invasive aesthetic procedures.
According to the American Society of Plastic Surgeons (ASPS), in 2020, plastic surgeons stopped performing elective surgical procedures for an average of 8.1 weeks in 2020 due to COVID-19, or 15% of the year, which indicates the decline in the total number of procedures performed. Moreover, in 2020, minimally invasive cosmetic procedures decreased slightly more than surgical procedures (16% vs. 14%) during stay-at-home orders, dropping for the first time in four years.
In addition, according to a research article by Dana E Bregman et al., published in Aesthetic Surgery Journal July 2020, in the United States, the total surgeons’ fees derived from both surgical and minimally invasive procedures in 2018 was approximately 5 billion dollars. The current pandemic will result in an approximately 20% decrease in collected fees which is expected to show impact on the market growth.
In Canada, the growing geriatric population is also fueling the market growth. As per the World population ageing 2019 report, in Canada, there were around 6.602 million people aged over 65 years in 2019, and the number is estimated to reach 11.436 million by 2050. The demand for aesthetic fillers is expected to increase due to increased attention on facial aesthetics among this population.
According to the American Society of Plastic Surgeons (ASPS), in 2019, 18.1 million cosmetic procedures were performed in the United States, out of which 16.3 million were minimally invasive. However, ASPS anticipates a decrease in the total number of cosmetic procedures in 2020 due to the COVID-19 pandemic, but it forecasts a strong demand for treatments as practices reopen for in-office procedures. As per the same source, as of 2019, around around 2,160,578 Hyaluronic acid cosmetic minimally-invasive procedures have been carried out in the United States.
The presence of key players in the United States that are launching new products in the market, gives an edge to the country in the global market. In January 2020, Revance Therapeutics, announced transformative aesthetics portfolio transaction with exclusive U.S. distribution agreement of FDA-Approved dermal fillers from Teoxane SA. TEOXANE SA RHA portfolio is the first and only range of FDA-approved dermal fillers for correction of dynamic wrinkles. In the future, with above mentioned factors it is expected to witness rapid growth over the forecast period.
The Facial Injectables Market is moderately competitive. The key players present in the market are making collaborations and product launch strategies in order to address the unmet aesthetic needs. Thereby, providing the physicians with new and better options, as well as augmenting the growth of the facial injectables market. The companies are also focusing on expanding their presence in the emerging markets and also trying to maintain strong distributor relationships. Some of the market players include AbbVie Inc (Allergan Plc), Ipsen SA, Medytox Inc., Merz Pharma, Sinclair Pharma Plc, among others.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Aesthetic Consciousness and Number of Cosmetic Procedures
4.2.2 Introduction of Cost-effective Facial Injectable
4.2.3 Ageing Population
4.3 Market Restraints
4.3.1 Side-effects of Available Products Limiting Adoption
4.3.2 Lack of Reimbursement Policies Supporting Cosmetic Procedures
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Wrinkle Relaxers
18.104.22.168 Botulinum Toxin
5.1.2 Dermal Fillers
22.214.171.124 Hyaluronic Acid
126.96.36.199 Fat Injection
188.8.131.52 Polylactic Acid
184.108.40.206 Polymethyl-methacrylate Microspheres (PMMA)
220.127.116.11 Calcium Hydroxylapatite
18.104.22.168 Other Dermal Fillers (Polyalkylimide etc.)
5.2 By Application
5.2.1 Facial Line Correction
5.2.2 Lip Augmentation
5.2.3 Face Lift
5.2.4 Acne Scar Treatment
5.2.5 Lipoatrophy Treatment
5.2.6 Other Applications (Chin augmentation and Earlobe Rejuvenation etc.)
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc (Allergan Plc)
6.1.2 Anika Therapeutics Inc.
6.1.3 Ipsen SA
6.1.4 Medytox Inc.
6.1.5 Merz Pharma
6.1.6 Galderma Pharma SA
6.1.7 Sanofi SA
6.1.8 Sinclair Pharma Plc
6.1.9 Suneva Medical Inc.
6.1.10 Teoxane Laboratories
6.1.11 Laboratories Vivacy SAS
6.1.12 SciVision Biotech Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS